Biotechnology firm RadioMedix has received a two-year $2 million grant from the U.S. National Cancer Institute (NCI) to support the clinical development of targeted alpha-emitter therapy for neuroendocrine tumors.
The phase II Small Business Innovation Research (SBIR) grant award serves as a continuation of a successfully completed phase I SBIR grant, according to the company. Specifically, the funds will be used to support an ongoing phase I study that is assessing the safety and effectiveness of the company's AlphaMedix (lead-212 octreotate analog) agent in adults with somatostatin receptor-expressing neuroendocrine tumors, RadioMedix said. The study is currently underway at the Excel Diagnostics and Nuclear Oncology Center in Houston.
